Trial
NCT03976648
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Lakefront Biotherapeutics NV
Collaborators
—
Condition
Systemic Sclerosis
Intervention
GLPG1690
Why stopped
The benefit-risk profile no longer supports continuing the studies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-29